（股份代號：6699） 關連交易 投資關連實體 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ANGELALIGN TECHNOLOGY INC. 時代天使科技有限公司 （於開曼群島註冊成立的有限公司） 於上海馬可菲斯的投資 董事會欣然宣佈，於2025年8月25日，本公司之全資附屬公司無錫時代天使與 上海馬可菲斯及上海馬可菲斯現有股東訂立投資協議，據此，無錫時代天使已 有條件同意以現金代價人民幣10.0百萬元認購上海馬可菲斯經擴大註冊股本的 5%。於投資完成後，本集團將實益擁有上海馬可菲斯約9.7%股權的權益。 上市規則涵義 截至本公告日期，本公司控股股東松柏投資集團直接及間接擁有上海馬可菲斯 超過30%股權。因此，上海馬可菲斯為上市規則第14A.07條項下本公司的關連 人士，而投資協議項下擬進行的交易構成上市規則第14A章項下的關連交易。 由於有關投資的最高適用百分比率超過0.1%但低於5%，故投資協議項下擬進行 的交易須遵守上市規則第14A章項 ...

EF001 EF001 免責聲明 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，董事會包括執行董事胡杰章先生、黃琨先生、宋鑫先生及董莉女士；非執行董事馮岱先生；獨立非執行董事韓小京 先生、石子先生及周浩先生。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 時代天使科技有限公司 | | 股份代號 | 06699 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年6月30日止六個月期間特別中期股息 | | 公告日期 | 2025年8月25日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 其他 | | 特別股息 | | | 股息性質 | 特別股息 | | 財政年末 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ANGELALIGN TECHNOLOGY INC. 時代天使科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6699） 截至2025年6月30日止六個月期間的中期業績公告 時代天使科技有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董 事」）會（「董事會」）欣然公佈本集團截至2025年6月30日止六個月期間（「報告期 間」）的未經審核綜合中期業績，連同截至2024年6月30日止六個月期間的比較數 字，有關業績已經由董事會審核委員會（「審核委員會」）審閱。 於本公告中，「我們」、「我們的」及「時代天使」指本公司及（除非文義另有規定） 本集團。除文義另有所指外，本公告所用詞彙與日期為2021年6月3日的本公司招 股章程（「招股章程」）所界定者具有相同涵義。 業績概要 1 • 我們截至2025年6月30日止六個月期間的收入為161.4百萬美元，較截至 2024年6月30日止六個月期間 ...

Core Viewpoint - A patent dispute has erupted between two major players in the global invisible orthodontics market, Align Technology and Times Angel, with significant implications for market share and competition in the industry [2][3][10]. Group 1: Patent Dispute Details - Align Technology has filed patent infringement lawsuits against Times Angel in the US, Europe, and China, claiming that Times Angel's products infringe on five of its US utility patents related to core technologies [2][4]. - Times Angel has publicly denied the infringement claims and expressed confidence in winning the case, asserting that the lawsuit will not materially affect its business growth [5][6]. - The patents in question include key innovations in multi-layer aligner materials and advanced treatment planning technologies, which are crucial to Align's intellectual property portfolio [4][10]. Group 2: Market Position and Competition - Times Angel has surpassed Align Technology in the Chinese market, achieving a market share of 41.9% in 2023, which is 10 percentage points higher than Align's 31.8% [3][7]. - The ongoing patent dispute could significantly impact market shares across three continents, with both companies vying for dominance in the rapidly growing invisible orthodontics sector [3][10]. - Align Technology has historically dominated the global market, but recent trends indicate a decline in its market share, particularly in China, where it has faced increasing competition from Times Angel [7][9]. Group 3: Industry Growth and Future Outlook - The global invisible orthodontics market is projected to grow from $18 billion in 2023 to over $40 billion by 2030, with a compound annual growth rate exceeding 12% [10]. - The outcome of the patent litigation may reshape the competitive landscape of the invisible orthodontics market, presenting both opportunities and challenges for the involved companies [10]. - Times Angel's recent international expansion efforts, including establishing subsidiaries in key markets, have positioned it as a formidable competitor to Align Technology [8][9].

Core Viewpoint - The company firmly denies the patent infringement allegations made by Aiqi Technology and plans to actively respond to the lawsuit [1] Group 1: Company Response - The company has a rich tradition of clinically driven innovation over its more than twenty-year history [1] - The Chief Business Officer and Senior Vice President, Rich Hirschland, stated that the competitor's patent claims are baseless and lack merit [1] - The company has invested significant resources in patent compliance since its inception [1] Group 2: Growth Outlook - The company anticipates that its growth will not be materially affected by the ongoing litigation [1] - Rich Hirschland expressed hope that this incident will raise awareness of the company's story and attract more global customers [1]

Core Viewpoint - The ongoing patent infringement lawsuit between Times Angel and Align Technology highlights the competitive dynamics in the invisible orthodontics market, with Times Angel asserting its market leadership in China despite Align's global dominance [1][2][3]. Group 1: Patent Infringement Lawsuit - Align Technology has filed a patent infringement lawsuit against Times Angel, claiming that Times Angel's products and software infringe on its patents related to multi-layer aligner materials and advanced treatment plans [2]. - Times Angel has denied the allegations, asserting that the claims are baseless and expressing confidence in winning the case [2]. Group 2: Market Position and Performance - Align Technology's core product, Invisalign, holds the top global market share, but Times Angel has surpassed it in the Chinese market, achieving a market share of 41.9% in 2023, which is 10 percentage points higher than Invisalign [1][3]. - Times Angel's revenue and net profit have shown significant growth, with a 28.2% increase in revenue and a 46.6% increase in net profit in 2024 compared to the previous year [4]. - The number of cases completed by Times Angel in China increased by 3.2% to 218,700, while cases outside China surged by 326.4% to 140,700 [4]. Group 3: Competitive Landscape - The competitive landscape in the Chinese invisible orthodontics market is intensifying, with new entrants like Zhengya gradually capturing market share from Times Angel [4][5]. - Times Angel has responded to market competition by strategically investing in the emerging brand Shuyazi, acquiring a 35% stake while maintaining independent operations [5].

Core Viewpoint - Angelalign Technology Co., Ltd. firmly denies the patent infringement allegations made by Align Technology Inc. and plans to actively respond to the claims [1][2] Group 1: Company Response - The company asserts that the patent claims from competitors are baseless and lack merit, emphasizing its long-standing commitment to patent compliance and innovation in the invisible orthodontics field [1] - Rich Hirschland, the Chief Business Officer, expresses confidence in winning the case and highlights the company's history of clinical-driven innovation over the past two decades [1] Group 2: Product Innovation - Angelalign has consistently led innovation in the invisible orthodontics sector, introducing award-winning products such as the angelButton system, angelHook system, and the A6 mandibular invisible orthodontic solution, among others [1] - The company focuses on creating a fair and healthy competitive environment, aiming to provide value to both doctors and patients through its advanced product offerings [1] Group 3: Market Position and Growth - The company anticipates that its growth will not be materially affected by the ongoing litigation, and it views the situation as an opportunity to raise awareness about its brand and attract more global customers [2]

Core Viewpoint - Angelalign Technology Co., Ltd. firmly denies the patent infringement allegations made by Align Technology Inc. and plans to actively respond to the claims [1] Group 1: Company Response - The company emphasizes its long history of clinical-driven innovation and asserts that the competitor's patent claims are baseless [1] - Rich Hirschland, the Chief Business Officer, states that the company has invested significant resources in patent compliance since its inception and is confident of winning the case [1] Group 2: Product Innovation - Angelalign has been a leader in the invisible orthodontics field, introducing award-winning products such as the angelButton™ system, angelHook system, and the A6 mandibular invisible orthodontic solution [1] - The company is committed to fostering a fair and healthy competitive environment in the market, creating value for both doctors and patients [1] Group 3: Market Position and Growth - The products of Angelalign have received high praise from doctors, and its intelligent manufacturing system effectively translates complex clinical concepts into actionable solutions [1] - The company anticipates that the lawsuit will not materially impact its growth and hopes to use this event to raise awareness of its story and attract more global customers [2]

Group 1 - The Hong Kong stock market experienced a rise and then a pullback, with the Hang Seng Index reaching a new high [1] - The National Healthcare Security Administration is publishing a list of drugs that have passed preliminary review for the "2025 National Medical Insurance Directory and Commercial Insurance Innovative Drug Directory," which will enter expert review and negotiation stages [1][2] - The Hong Kong Innovative Drug Selected ETF (520690) saw a nearly 2.5% increase, with a trading volume exceeding 20 million and a turnover rate over 5%, indicating strong market interest [1] Group 2 - The dual-track policy of basic medical insurance and commercial insurance for innovative drugs signals a payment closure model, suggesting that "true innovation is easier to scale" [2] - The performance of innovative drugs is expected to be positively impacted by the dual-track payment system and significant business development opportunities, leading to a systematic revaluation of the Chinese innovative drug sector [2] - The Hang Seng Medical ETF (513060) is benefiting from the dual advantages of technology penetration and market expansion, particularly in AI healthcare and innovative drug companies [3]

近日，由上海交通大学医学院附属第九人民医院（以下简称"上海九院"）口腔正畸科团队与时代天 使合作研发的"数字化青少年小下颌畸形矫形器的研发及产业化"项目，凭借其创新性与卓越的产业化成 果，荣获"上海产学研合作优秀项目奖"一等奖。这一殊荣标志着项目在科研创新、学术推广和成果转化 方面取得了一个里程碑，也彰显了上海九院和时代天使在推动医疗健康产业高质量发展中踔厉前行、踏 实耕耘的精神风貌。 上海九院口腔正畸科房兵教授、时代天使CEO胡杰章 "上海产学研合作优秀项目奖"由上海市科委批准并经国家科技部备案，旨在表彰和鼓励产学研深度 合作、促进技术创新和成果转化。一等奖项目需在技术创新性、产业化成果和社会影响力等方面表现突 出。本次获奖的"数字化青少年小下颌畸形矫形器"项目，正是一次产学研结合、医工交叉的成功实践。 为了解决青少年小下颌畸形这一发病率高、对青少年咬合、容貌、心理健康有重要影响的牙颌面畸 形问题，上海九院与时代天使携手同行，集结了口腔临床医学研究人员、生物力学专家、工程师和产品 研发人员，充分发挥上海九院在口腔医学临床研究方面和时代天使在隐形矫治技术上的优势，深入分析 颌骨生长发育规律和现有器械的局限性， ...